Meeting News
Meeting News
Cecilia BrownMyeloma | November 15, 2022
No dose-limiting toxicities occurred in patients with relapsed/refractory multiple myeloma who were treated with agenT-797...
Read More
Cecilia BrownIndolent B-Cell Lymphoma | November 15, 2022
Patients with LBCL received prophylactic anakinra to reduce the risk of cytokine release syndrome following CAR-T.
Leah SherwoodHodgkin Lymphoma | November 15, 2022
Penpulimab demonstrated a good safety profile in patients with relapsed/refractory classical Hodgkin lymphoma.
Leah SherwoodMyeloproliferative Neoplasms | October 28, 2022
A large analysis of real-world treatment outcomes in patients with myelofibrosis who were treated with ruxolitinib.
Leah SherwoodMyeloproliferative Neoplasms | October 28, 2022
Momelotinib led to “superior” symptom and spleen responses and transfusion independence rates compared to danazol.
Leah SherwoodMyeloproliferative Neoplasms | October 28, 2022
As TKIs have become available to patients, survival for those with CML has significantly improved but disparities.
Leah SherwoodMyeloproliferative Neoplasms | October 27, 2022
VERIFY, a phase III trial of the hepcidin mimetic rusfertide (PTG-300), is now enrolling patients with PV.
Leah SherwoodMyeloproliferative Neoplasms | October 27, 2022
IFN alpha-2 influences the regulation of several ECM genes involved in tissue remodeling.
Leah SherwoodAggressive B-Cell Lymphoma | October 27, 2022
Does the route of administration matter in preventing CNS relapse in agressive B-cell lymphomas?
Leah SherwoodAcute Myeloid Leukemia | October 21, 2022
Marina Konopleva, MD, PhD, discusses venetoclax resistance in AML during SOHO 2022
Leah SherwoodMantle Cell Lymphoma | October 17, 2022
Jia Ruan, spoke on emerging treatment options for MCL in this interview from SOHO 2022.
Leah SherwoodMyeloproliferative Neoplasms | October 12, 2022
A retrospective study observed a three-year OS rate of 66.7% in primary MF patients and 55.6% in secondary MF patients...
Leah SherwoodAcute Myeloid Leukemia | October 12, 2022
Gilteritinib plus induction and consolidation chemotherapy demonstrated acceptable safety outcomes and efficacy in patients ...
Leah SherwoodAcute Myeloid Leukemia | October 10, 2022
Dr. Konopleva spoke to Blood Cancers Today during the 2022 SOHO Annual Meeting.
Leah SherwoodChronic Lymphocytic Leukemia | October 10, 2022
Dr. Coombs discussed these challenges during the 10th Annual Meeting of the Society of Hematologic Oncology.
Leah SherwoodMeeting News | October 6, 2022
Autologous chimeric antigen receptor (CAR) T-cell therapies have shown
Leah SherwoodTransplantation & Cellular Therapy | October 6, 2022
Carlos de Lima, MD, stopped by the Blood Cancers Today booth at the 2022 SOHO Annual Meeting to give his advice...
Kerri FitzgeraldMantle Cell Lymphoma | October 5, 2022
Event-free survival at 24 months may become an important clinical endpoint in mantle cell lymphoma in the future.
Leah SherwoodMantle Cell Lymphoma | October 5, 2022
Tycel Phillips, MD, discusses the role of targeted therapies in frontline mantel cell lymphoma (MCL).
Leah SherwoodMantle Cell Lymphoma | October 5, 2022
Jia Ruan, MD, PhD, discusses emerging treatment options for mantle cell lymphoma at the 2022 SOHO Annual Meeting.
Advertisement
Editorial Board

Advertisement